These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 17868503)

  • 1. Efficacy, tolerability and comfort of a 0.3% hypromellose gel ophthalmic lubricant in the treatment of patients with moderate to severe dry eye syndrome.
    Tauber J
    Curr Med Res Opin; 2007 Nov; 23(11):2629-36. PubMed ID: 17868503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.
    Sullivan LJ; McCurrach F; Lee S; Taylor HR; Rolando M; Marechal-Courtois C; Creuzot-Garcher C; Easty DL; Karabatsas C; Bingh Hoh M; Faschinger C; Laroche L
    Ophthalmology; 1997 Sep; 104(9):1402-8. PubMed ID: 9307633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA).
    El Fekih L; Khairallah M; Ben Amor H; Mahmoud A; Chiambaretta F; Messaoud R
    J Fr Ophtalmol; 2024 Sep; 47(7):104169. PubMed ID: 38838456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye.
    Khanal S; Tomlinson A; Pearce EI; Simmons PA
    Cornea; 2007 Feb; 26(2):175-81. PubMed ID: 17251808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.
    Kinoshita S; Awamura S; Nakamichi N; Suzuki H; Oshiden K; Yokoi N;
    Am J Ophthalmol; 2014 Mar; 157(3):576-83.e1. PubMed ID: 24246575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label evaluation of HP-Guar gellable lubricant eye drops for the improvement of dry eye signs and symptoms in a moderate dry eye adult population.
    Hartstein I; Khwarg S; Przydryga J
    Curr Med Res Opin; 2005 Feb; 21(2):255-60. PubMed ID: 15801996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
    Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
    Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study.
    Wang TJ; Wang IJ; Ho JD; Chou HC; Lin SY; Huang MC
    Clin Ther; 2010 Jan; 32(1):44-52. PubMed ID: 20171410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
    Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
    Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial.
    Simmons PA; Carlisle-Wilcox C; Chen R; Liu H; Vehige JG
    Clin Ther; 2015 Apr; 37(4):858-68. PubMed ID: 25659956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.
    Lievens C; Berdy G; Douglass D; Montaquila S; Lin H; Simmons P; Carlisle-Wilcox C; Vehige J; Haque S
    Cont Lens Anterior Eye; 2019 Aug; 42(4):443-449. PubMed ID: 30573298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of an Eye Drop Based on 0.6% Povidone-Iodine Nanoemulsion in Dry Eye Patients.
    Oliverio GW; Spinella R; Postorino EI; Inferrera L; Aragona E; Aragona P
    J Ocul Pharmacol Ther; 2021 Mar; 37(2):90-96. PubMed ID: 33370213
    [No Abstract]   [Full Text] [Related]  

  • 19. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trial of topical antibacterial Manuka (Leptospermum species) honey for evaporative dry eye due to meibomian gland dysfunction.
    Albietz JM; Schmid KL
    Clin Exp Optom; 2017 Nov; 100(6):603-615. PubMed ID: 28585260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.